No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Reported Earlier, Autolus Therapeutics Revealed New Data Supporting Obe-cel's Clinical And Economic Benefits At ASH 2024
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics: Undervalued Potential in ALL Treatment With Obe-cel
Autolus Therapeutics Plc (AUTL): A Bull Case Theory
Positive Outlook for Autolus Therapeutics Driven by Regulatory Approval and Competitive Positioning in CAR-T Therapy